Supplemental Biologics License Application

Acronym

Definition

SBLA

SBLA

Small Business Loans Act (Canada)

SBLA

Smash Bros Los Angeles (dance and music group; California)

SBLA

Small Business Loans Association (Saskatchewan, Canada)

SBLA

State Boating Law Administrator

SBLA

Sealed Bipolar Lead Acid (battery)

SBLA

Self-Bounding Learning Algorithm

References in periodicals archive	?		Acronyms browser	?		Full browser	?
The FDA has accepted for filing and review, and has granted priority review status for a supplemental Biologics License Application (sBLA) for use of Zevalin as consolidation therapy in patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy and expects a decision regarding the sBLA in early April, 2009. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement ... by BIOTECH Patent News Foodand Drug Administration (FDA) has approved an efficacy supplemental biologics license application (sBLA) for ONTAK' (denileukin diftitox) solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-celllymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+). FDA Grants Full Approval to ONTAK' (denileukin diftitox) For Use in ... by ACN Newswire Also in the first quarter, the company submitted a Supplemental Biologics License Application (SBLA) with the U. ALLERGAN REPORTS FIRST QTR. 8.8% INCREASE IN WORLDWIDE SALES by Biotech Financial Reports	SUPF SUPG SUPGV SUPI SUPIDEN SUPIM SUPINSMAT SUPINSP SUPINTREP SUPIR SUPKEM SUPL SUPLAN SUPLECAM SUPLOS SUPLS SUPM SUPMIS SUPN SUPO SUPP SUPPAC SUPPH SUPPIIN SUPPL Supplemental Biologics License Application SUPPLIERS SUPPLOT SUPPO SUPPORT SUPPR SUPPREP SUPPT SUPR SUPRA SUPRA- SUPRAD SUPRAID SUPREM SUPREP SUPRI SUPS SUPSALV SUPSD SUPSGT SUPSHIP SUPSHIPNN SUPSIT SUPT SUPTG SUPU	Supplément de Revenu Garanti Supplement Research Foundation supplement to a will Supplement to an Abbreviated New Drug Submission Supplement to Final Environmental Impact Statement Supplement to HIV/AIDS Surveillance Supplement to the Final Environmental Statement Supplement/Supplemental supplemental supplemental supplemental Supplemental Address Supplemental Advance Notice of Proposed Rulemaking Supplemental Agreement Supplemental Aid to Maintenance Supplemental Aid to the Blind supplemental air supplemental air supplemental air supplemental air Supplemental Air Carrier Conference Supplemental Amortization Equalization Disbursement Supplemental angle Supplemental Annuity Collective Trust Supplemental Appropriation Supplemental Assay Method Supplemental Assembly Supplemental Aviation Spares Support Supplemental bill Supplemental bill Supplemental Biologics License Application Supplemental Brief for Appellants Supplemental Brief for Appellants STATEMENT Supplemental Camera and Maneuvering Platform Supplemental Card Indicator Supplemental Channel Supplemental Channel Request Message Supplemental Channel Request Mini Message Supplemental Channel Type supplemental chords Supplemental Code Channel Supplemental Code Channel Type supplemental conditions Supplemental Control Unit Supplemental Coolant Additive Supplemental Corridor Air Defense System Supplemental Data Collection Instrument Supplemental Data for Provisioning Supplemental Defense Appropriations Act Supplemental Defense Appropriations Act Supplemental Definition of Requirement Supplemental Descriptive Data Table Supplemental Design Requirements Document Supplemental Dictionary Supplemental Disability Income Rider Supplemental Draft Environmental Impact Report

References in periodicals archive

Acronyms browser

Full browser

The FDA has accepted for filing and review, and has granted priority review status for a supplemental Biologics License Application (sBLA) for use of Zevalin as consolidation therapy in patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy and expects a decision regarding the sBLA in early April, 2009.

Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement ... by BIOTECH Patent News

Foodand Drug Administration (FDA) has approved an efficacy supplemental biologics license application (sBLA) for ONTAK' (denileukin diftitox) solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-celllymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+).

FDA Grants Full Approval to ONTAK' (denileukin diftitox) For Use in ... by ACN Newswire

Also in the first quarter, the company submitted a Supplemental Biologics License Application (SBLA) with the U.

ALLERGAN REPORTS FIRST QTR. 8.8% INCREASE IN WORLDWIDE SALES by Biotech Financial Reports